Oncology | Phase II Developments | FRANCE

Sanofi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Sanofi's Emerging Oncology Pipeline Highlighted at the AACR Virtual Annual Meeting II

Lead Product(s): SAR439859

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 15, 2020

Details:

Preclinical data for Sanofi's investigational compounds in breast, lung, multiple myeloma and other cancers will be featured at the American Academy of Cancer Research (AACR) Virtual Annual Meeting II on June 22-24.

Sanofi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Sanofi To Present Oncology Strategy, Provide Update On Portfolio And Emerging Pipeline

Lead Product(s): SAR439859

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 02, 2020

Details:

The four areas of strategic focus within oncology, including multiple myeloma, skin, lung, and breast cancers. Sanofi’s four anchor oncology treatments include Sarclisa® (isatuximab-irfc) and Libtayo® (cemiplimab-nwlc), and the pipeline programs.

Innate Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

France France

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

U.S. Food and Drug Administration Lifts Partial Clinical Hold on Lacutamab TELLOMAK Trial in Advanced T-cell Lymphomas

Lead Product(s): Lacutamab,Gemcitabine,Oxaliplatin

Therapeutic Area: Oncology Product Name: IPH4102

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 24, 2020

Details:

The FDA decision is based on a quality assessment of a new Good Manufacturing Practice (GMP)-certified batch that has been successfully manufactured for the lacutamab clinical development program, including the TELLOMAK trial.

Innate Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

France France

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Innate Pharma to Present New Efficacy Data for Monalizumab in Combination with Cetuximab in Head and Neck cancer at the ASCO20

Lead Product(s): Monalizumab,Cetuximab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 14, 2020

Details:

Darolutamide significantly reduced risk of death by 31% in men with non-metastatic castration-resistant prostate cancer (nmCRPC) and delayed the time to pain progression, time to first initiation of cytotoxic chemotherapy, and time to first symptomatic skeletal event (SSE).

MAbSilico solutions

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

OSE Immunotherapeutics Partners with MAbSilico

Lead Product(s): Tedopi,Nivolumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: OSE Immunotherapeutics SA

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration February 12, 2020

Details:

Agreement capitalizes on artificial intelligence and deep learning to develop therapeutic monoclonal antibodies, including novel bispecific antibodies (BiCKI® platform).

Cellectis

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Iovance Biotherapeutics to license certain TALEN technology from Cellectis

Lead Product(s): Tumor infiltrating lymphocytes

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Iovance Biotherapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 13, 2020

Details:

Iovance Biotherapeutics will use TALEN® Technology from Cellectis to develop Gene-Edited TIL that have been genetically edited to create more potent cancer therapeutics.

Innate Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

France France

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitment in Sezary Syndrome and mycosis fungoides

Lead Product(s): Lacutamab,Gemcitabine,Oxaliplatin

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2020

Details:

Innate Pharma will take the operational measures to reactivate the lacutamab TELLOMAK trial in Sézary syndrome and MF in France and UK, where regulatory agencies have authorized it.

Innate Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

France France

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Innate Pharma Provides Update from Regulatory Agencies on Lacutamab TELLOMAK Trial

Lead Product(s): Lacutamab,Gemcitabine,Oxaliplatin

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 09, 2020

Details:

Innate Pharma decided to suspend enrollment of new patients in the TELLOMAK trial, except in Italy where the clinical trial has been suspended.

Find

Find Oncology Drugs in Phase II Clinical Development in FRANCE

France

Product Type

Companies

Sanofi

Sanofi's Emerging Oncology Pipeline Highlighted at the AACR Virtual Annual Meeting II

Sanofi

Sanofi To Present Oncology Strategy, Provide Update On Portfolio And Emerging Pipeline

Innate Pharma

U.S. Food and Drug Administration Lifts Partial Clinical Hold on Lacutamab TELLOMAK Trial in Advanced T-cell Lymphomas

Innate Pharma

Innate Pharma to Present New Efficacy Data for Monalizumab in Combination with Cetuximab in Head and Neck cancer at the ASCO20

MAbSilico solutions

OSE Immunotherapeutics Partners with MAbSilico

Cellectis

Iovance Biotherapeutics to license certain TALEN technology from Cellectis

Innate Pharma

French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitment in Sezary Syndrome and mycosis fungoides

Innate Pharma

Innate Pharma Provides Update from Regulatory Agencies on Lacutamab TELLOMAK Trial